KoDiscovery NEWSNovember 7, 2022 KAT-101 Clinical Trial Announcement ClinicalTrials.gov Identifier: NCT05603572 |
|
|
It is my great pleasure to share with you that, as of 11/2/22, NewG Lab Pharma’s clinical trial for Dr. Ko’s KAT-101 formula for hepatocellular carcinoma has been listed on ClinicalTrials.gov and is now recruiting patients. You may find all of the details of the clinical trial by following the link below or using the ClinicalTrials.gov Identifier of NCT05803572. Here is a brief synopsis. This is a multi-center, open-label, three-cohort, phase I/II(a) clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KAT-101 in subjects with hepatocellular carcinoma. The three cohorts will be as follows: This study will be initiated at three locations in South Korea shown below. |
|
|
Kyungpook National University Hospital, Daegu, Republic of Korea |
|
|
Samsung Medical Center, Seoul, Republic of Korea |
|
|
Seoul National University Hospital, Seoul, Republic of Korea |
|
|
As of 11/7/22, if you go to the clinicaltrials.gov website and search trials for “hepatocellular carcinoma” you will find 2,589 listed results. If you modify your search criteria to add “3BP” or “3-bromopyruvate” you will not find any studies listed. However, if you add “KAT” to your search criteria, you will find clinical trial identifier NCT05603572, which is the clinical trial utilizing Dr. Ko’s patented formulation of 3BP. So, as you share this information with others, please let them know that this is not specifically a study of the small molecule “3-bromopyruvate" or "3BP” but rather a study of Dr. Ko’s 3BP formulation, known as KoDiscovery Anticancer Technology, or KAT. |
|
|
One last important reminder is that, unlike the majority of phase I clinical trials, this one is for treating patients with all stages of hepatocellular carcinoma to determine optimal dosing. Therefore, it is very significant that actionable data will be generated from the enrollment of the first patient, which will help direct and expedite future studies that are necessary to bring KAT to full FDA approval. Here is the link to the ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT05603572 It is the hope of NewG Lab Pharma that with the implementation of phase II, this study will be expanded into the U.S., perhaps as soon as 2023. As official sites are identified and details are finalized, we will keep you informed. In the meantime, please share this exciting news and the link above with your friends and know that Dr. Ko is now making substantial progress on multiple fronts. Her progress and ultimate success would not be possible without the continued support, positive thoughts, prayers and financial support that you continue to give her. And, as always, she is very grateful to you all. I will keep you updated as I am given authorization to do so. Blessings and peace to you all. Take care, Barry Argroves KoDiscovery Project Manager |
|
|
|
|